 |
|
|
As an aid to the treatment of respiratory disease in cattle, horses, pigs, dogs and cats where mucus is a complicating factor.
Horses
•Acute and chronic bronchitis
•Sinusitis
•Virus pneumonia
•Equine influenza
•All respiratory infections
•When an injectable mucolytic is deemed necessary, Bisolvon Injection can be used to initiate treatment. This may be particularly relevant in anorexic horses and foals.
Cattle, calves, pigs, piglets, dogs and cats
- all respiratory infections.
|
|
Presentation
Binixin Injection is a clear, sterile, injectable, ready to use, aqueous solution for slow intravenous injection in cattle and horses. Each ml contains Flunixin 50 mg (as Flunixin Meglumine) and Phenol 5 mg (Preservative).
Uses
Cattle
For the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever).
Binixin Injection may be used as adjunctive therapy in the treatment of acute mastitis.
Horses
For the alleviation of inflammation and pain associated with musculo-skeletal disorders.
It is also indicated for the alleviation of visceral pain associated with colic.
|
|
Dosage and administration
The dose is administered by slow intravenous injection.
Cattle: The recommended dose is 2 ml Binixin Injection per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of the acute inflammatory condition should be determined and treated with concomitant therapy.
Horses: For use in equine musculo-skeletal disorders: the recommended dose is 1 ml Binixin Injection per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days according to clinical response.
For use in equine colic: the recommended dose is 1 ml Binixin Injection per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously and repeated once or twice if signs of colic recur. The cause of colic should be determined and treated with concomitant therapy.
Use During Pregnancy and Lactation
Do not administer to pregnant mares. Studies to demonstrate safety in pregnant mares have not been conducted.
|
|
Contra-indications, warnings, etc
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Do not administer to racehorses within 8 days of racing.
Do not mix Binixin Injection with other medicaments prior to administration.
Administer by slow intravenous injection . Avoid intra-arterial injection, which may result in collapse.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Monitor drug compatibility closely where adjunctive therapy is required. As with other NSAIDs, Binixin Injection may potentiate the effects of Warfarin and other drugs.
Due to their common mode of action, flunixin may potentiate and be potentiated by other NSAIDs which act by interfering with prostaglandin synthesis.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects. Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent anti-microbial therapy should be instigated.
Prolonged use of NSAIDs, including flunixin, may predispose or lead to gastrointestinal irritation, and in severe cases, ulceration.
Repeated use in equine colic may mask signs of pain.
Do not exceed the stated dose or duration of treatment. Tolerance trials in horses and cattle confirmed excellent tolerance at twice the recommended dose.
User safety
Avoid accidental self injection.
Avoid contact with the eyes and direct contact with the skin. Gloves should be worn during administration. Wash hands after use. In the case of accidental contact with the eyes, rinse immediately with plenty of eater and seek medical advice.
The product may cause reaction in sensitive individuals. If you have a known hypersensitivity to non-steroidal anti-inflammatory products, do not handle the product. Reactions may be serious.
Withdrawal periods
Horses:
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
Cattle
Meat:
Animals may not be slaughtered for human consumption during treatment.
Cattle may be slaughtered for human consumption only 8 days after the last treatment.
Milk:
Milk from lactating cows should be discarded during treatment. Milk from cows should only be taken for human consumption from 12 hours following cessation of treatment.
Pharmaceutical precautions
Do not store above 25°C.
Following withdrawal of the first dose, use the product within 28 days. Discard unused material.
Any unused product or waste material should be disposed of in accordance with national requirements.
|
|
Legal category
POM-V
Packaging Quantities
Individually packed multi dose clear type II glass bottles of 50 ml and 100 ml.
Further information
Flunixin meglumine is a non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties. It acts by interfering with the arachidonic acid pathway of protaglandin synthesis.
|
|
|
